Pamela Bowman1,2, Frances Mathews3,2, Fabrizio Barbetti4,5, Maggie H Shepherd3,2, Janine Sanchez6, Barbara Piccini7, Jacques Beltrand8,9,10, Lisa R Letourneau-Freiberg11, Michel Polak8,9,10, Siri Atma W Greeley11, Eamon Rawlins2, Tarig Babiker2, Nicholas J Thomas2, Elisa De Franco2, Sian Ellard2, Sarah E Flanagan2, Andrew T Hattersley. 1. Exeter NIHR Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, U.K. p.bowman@exeter.ac.uk. 2. Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K. 3. Exeter NIHR Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, U.K. 4. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy. 5. Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. 6. Miller School of Medicine, University of Miami, Miami, FL. 7. Regional Center for Pediatric Diabetes, Meyer University Children's Hospital, Florence, Italy. 8. Service d'Endocrinologie, Gynécologie et Diabétologie Pédaitrique, APHP Centre, Université de Paris, Paris, France. 9. INSERM U1016, Paris, France. 10. Institut IMAGINE, Paris, France. 11. Kovler Diabetes Center, The University of Chicago, Chicago, IL.
Abstract
OBJECTIVE: ABCC8 mutations cause neonatal diabetes mellitus that can be transient (TNDM) or, less commonly, permanent (PNDM); ∼90% of individuals can be treated with oral sulfonylureas instead of insulin. Previous studies suggested that people with ABCC8-PNDM require lower sulfonylurea doses and have milder neurological features than those with KCNJ11-PNDM. However, these studies were short-term and included combinations of ABCC8-PNDM and ABCC8-TNDM. We aimed to assess the long-term glycemic and neurological outcomes in sulfonylurea-treated ABCC8-PNDM. RESEARCH DESIGN AND METHODS: We studied all 24 individuals with ABCC8-PNDM diagnosed in the U.K., Italy, France, and U.S. known to transfer from insulin to sulfonylureas before May 2010. Data on glycemic control, sulfonylurea dose, adverse effects including hypoglycemia, and neurological features were analyzed using nonparametric statistical methods. RESULTS: Long-term data were obtained for 21 of 24 individuals (median follow-up 10.0 [range 4.1-13.2] years). Eighteen of 21 remained on sulfonylureas without insulin at the most recent follow-up. Glycemic control improved on sulfonylureas (presulfonylurea vs. 1-year posttransfer HbA1c 7.2% vs. 5.7%, P = 0.0004) and remained excellent long-term (1-year vs. 10-year HbA1c 5.7% vs. 6.5%, P = 0.04), n = 16. Relatively high doses were used (1-year vs. 10-year dose 0.37 vs. 0.25 mg/kg/day glyburide, P = 0.50) without any severe hypoglycemia. Neurological features were reported in 13 of 21 individuals; these improved following sulfonylurea transfer in 7 of 13. The most common features were learning difficulties (52%), developmental delay (48%), and attention deficit hyperactivity disorder (38%). CONCLUSIONS: Sulfonylurea treatment of ABCC8-PNDM results in excellent long-term glycemic control. Overt neurological features frequently occur and may improve with sulfonylureas, supporting early, rapid genetic testing to guide appropriate treatment and neurodevelopmental assessment.
OBJECTIVE: ABCC8 mutations cause neonatal diabetes mellitus that can be transient (TNDM) or, less commonly, permanent (PNDM); ∼90% of individuals can be treated with oral sulfonylureas instead of insulin. Previous studies suggested that people with ABCC8-PNDM require lower sulfonylurea doses and have milder neurological features than those with KCNJ11-PNDM. However, these studies were short-term and included combinations of ABCC8-PNDM and ABCC8-TNDM. We aimed to assess the long-term glycemic and neurological outcomes in sulfonylurea-treated ABCC8-PNDM. RESEARCH DESIGN AND METHODS: We studied all 24 individuals with ABCC8-PNDM diagnosed in the U.K., Italy, France, and U.S. known to transfer from insulin to sulfonylureas before May 2010. Data on glycemic control, sulfonylurea dose, adverse effects including hypoglycemia, and neurological features were analyzed using nonparametric statistical methods. RESULTS: Long-term data were obtained for 21 of 24 individuals (median follow-up 10.0 [range 4.1-13.2] years). Eighteen of 21 remained on sulfonylureas without insulin at the most recent follow-up. Glycemic control improved on sulfonylureas (presulfonylurea vs. 1-year posttransfer HbA1c 7.2% vs. 5.7%, P = 0.0004) and remained excellent long-term (1-year vs. 10-year HbA1c 5.7% vs. 6.5%, P = 0.04), n = 16. Relatively high doses were used (1-year vs. 10-year dose 0.37 vs. 0.25 mg/kg/day glyburide, P = 0.50) without any severe hypoglycemia. Neurological features were reported in 13 of 21 individuals; these improved following sulfonylurea transfer in 7 of 13. The most common features were learning difficulties (52%), developmental delay (48%), and attention deficit hyperactivity disorder (38%). CONCLUSIONS: Sulfonylurea treatment of ABCC8-PNDM results in excellent long-term glycemic control. Overt neurological features frequently occur and may improve with sulfonylureas, supporting early, rapid genetic testing to guide appropriate treatment and neurodevelopmental assessment.
Authors: Ethel Codner; Sarah E Flanagan; Francisca Ugarte; Hernán García; Teresa Vidal; Sian Ellard; Andrew T Hattersley Journal: Diabetes Care Date: 2007-03-02 Impact factor: 19.112
Authors: Trang T Ly; David M Maahs; Arleta Rewers; David Dunger; Abiola Oduwole; Timothy W Jones Journal: Pediatr Diabetes Date: 2014-07-12 Impact factor: 4.866
Authors: Jussi Aittoniemi; Constantina Fotinou; Tim J Craig; Heidi de Wet; Peter Proks; Frances M Ashcroft Journal: Philos Trans R Soc Lond B Biol Sci Date: 2009-01-27 Impact factor: 6.237
Authors: L Aguilar-Bryan; C G Nichols; S W Wechsler; J P Clement; A E Boyd; G González; H Herrera-Sosa; K Nguy; J Bryan; D A Nelson Journal: Science Date: 1995-04-21 Impact factor: 47.728
Authors: Meena Rafiq; Sarah E Flanagan; Ann-Marie Patch; Beverley M Shields; Sian Ellard; Andrew T Hattersley Journal: Diabetes Care Date: 2007-11-19 Impact factor: 19.112
Authors: P Bowman; E Broadbridge; B A Knight; L Pettit; S E Flanagan; M Reville; J Tonks; M H Shepherd; T J Ford; A T Hattersley Journal: Diabet Med Date: 2016-05-21 Impact factor: 4.359
Authors: Can Thi Bich Ngoc; Vu Chi Dung; Elisa De Franco; Nguyen Ngoc Lan; Bui Phuong Thao; Nguyen Ngoc Khanh; Sarah E Flanagan; Maria E Craig; Nguyen Huy Hoang; Tran Minh Dien Journal: Front Endocrinol (Lausanne) Date: 2022-04-19 Impact factor: 6.055